A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Pesampator (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- Sponsors Biogen; Pfizer
- 12 Oct 2016 Status changed from not yet recruiting to discontinued.
- 09 Aug 2016 New trial record